Compared to the isotype IgG-treated controls, CD226 blockade remarkably reduced IFN-γ and TNF-α production by TIGIT+CD226+ CD4 T cells in both patients with DM (n = 5) and HCs (n = 5) (Fig. 5). The gene discussed is CD4; the disease is dermatomyositis.